Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with primary liver cancer (hepatocellular carcinoma), confirmed either through a tissue sample or by established medical guidelines.
• People whose liver cancer was classified as BCLC stage C when their first round of systemic (whole-body) treatment began.
• People whose cancer has shown limited, measurable progression (in 1–5 specific spots, across no more than 1–3 areas of the body) during their current first-line treatment, confirmed by scans or tissue testing, and fitting specific internationally recognised patterns of limited spread.
• People whose current first-line treatment kept the cancer stable for at least 3 months before these limited areas of progression appeared, and who have not previously had another first-line treatment fail due to progression.
• People whose areas of limited progression are suitable for radiotherapy and include at least one lesion measurable by standard imaging criteria (RECIST v1.1).
• People whose liver function scores are within an acceptable range (Child-Pugh score of 7 or below).
• People with a general physical wellbeing score of 0 or 1 on the standard ECOG scale, meaning they are fully active or have only minor limitations in daily activities.
• People aged between 18 and 75 years.
• People who are willing and able to give written consent and to follow the study's treatment and follow-up requirements.
• People for whom tumour and blood samples are available for research testing.

Who may not be able to join:

• People who received their first-line systemic treatment as a preventative (adjuvant) therapy after surgery intended to cure their liver cancer.
• People whose cancer progressed within 3 months of starting their first-line treatment.
• People diagnosed with a mixed liver cancer type known as combined hepatocellular-cholangiocarcinoma.
• People who experienced a serious (grade 3 or higher) side effect from their first-line treatment.
• People who have cancer spread to the brain, the lining of the abdomen, or the fatty tissue in the abdomen, with associated bleeding after first-line treatment.
• People who have previously received radiation therapy to the same area now showing limited progression.
• People with active, untreated hepatitis B, defined as a positive hepatitis B surface antigen test combined with hepatitis B virus levels above the normal range at the participating centre.
• People whose areas of limited progression cannot be treated with radiotherapy.
• People with an alpha-fetoprotein (AFP) blood protein level of 10,000 ng/mL or higher at the time the limited progression was identified.
• People diagnosed with another cancer (other than certain treated skin cancers or carcinoma in situ) within the 3 years before joining the study.
• People currently taking part in another interventional clinical trial, or who have received another experimental drug or device within the past 4 weeks.
• People with an autoimmune disease or any condition requiring long-term steroid use.
• People with severe problems affecting the heart, lungs, kidneys, or other vital organs, active infections (other than viral hepatitis), or other serious health conditions that could prevent safe participation in treatment.
• People with a known or suspected allergy to any of the study drugs or related medications.
• People who have had an organ transplant.
• People who are pregnant or breastfeeding.
• People whom the trial investigators consider unsuitable for any other reason that could affect participation or the reliability of study results (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.